Results 271 to 280 of about 152,178 (350)

Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study. [PDF]

Breast Cancer (Dove Med Press)
Chen L, Huang J, Chen X, Lan X, Song L, Xie X, Bai X, Du C.   +7 more
europepmc   +1 more source

Trastuzumab subcutáneo en el tratamiento del cáncer de mama HER2 positivo

, 2016
Enrique Díaz-Cantón, Martha Vega
openalex   +2 more sources

Case Report: Pathological complete response yet early brain relapse in HER2-positive breast cancer: a case-based review. [PDF]

Front Immunol
Feng J, Tong Y, Zhang Z, He Y.
europepmc   +1 more source

Reducing treatment burden in HER2+ breast cancer: Evaluating subcutaneous injection methods for pertuzumab/trastuzumab combination therapy. [PDF]

Medicine (Baltimore)
Zheng R, Liang Y, Chen S, Liu J, Yuan S, Li S, Liu X.   +6 more
europepmc   +1 more source

Pathologic Complete Response Rates in Early-Stage Human Epidermal Growth Factor 2 (HER2)-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Anti-HER2 Therapy: A Real-World Experience. [PDF]

Cureus
Mokfi R, Boutaagount F, Maskrout M, Bennour S, Senoussi C, Nadif L, Berrada N, Lamine L, Bouhou I, Naciri S, Rais G.   +10 more
europepmc   +1 more source

Prognostic and predictive significance of neutrophil/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer. [PDF]

Sci Rep
Cao J, Pang J, Li Y, Wang S, Xiao Z, Ding N.   +5 more
europepmc   +1 more source

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials [PDF]

, 2017
et al,, Mutch, David G
core   +1 more source

HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer. [PDF]

Cancer Med
Lee S, Kahn AM, Rozenblit M, George MA, Naranjo Ortiz C, Lustberg MB.   +5 more
europepmc   +1 more source

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

Einstein (Sao Paulo)
Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, Serrano Usón Junior PL, Kaliks R, Beal JR.   +8 more
europepmc   +1 more source

HER2 expression in breast cancer: evidence gaps and challenges. [PDF]

NPJ Precis Oncol
Atallah NM, Quinn C, Rakha E.
europepmc   +1 more source